Efficacy of T2 in active Crohn's disease: A prospective study report

Digestive Diseases and Sciences

Volumn 52, Issue 8, 2007, Pages 1790-1797

  Ren, Jianan ^a,b   Tao, Qingsong ^a   Wang, Xinbo ^a   Wang, Zhiming ^a   Li, Jieshou ^a  

^a NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Crohn's disease; Crohn's disease activity index; Crohn's Disease Endoscopic Index of Severity; Interleukin 1 ; Tripterygium wilfordii; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; TRIPTERYGIUM WILFORDII EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHINESE MEDICINE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ISOLATION; DRUG SAFETY; ENDOSCOPY; FEMALE; HEADACHE; HUMAN; ILEUM; MALE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; REMISSION; STATISTICAL SIGNIFICANCE; TRIPTERYGIUM; TRIPTERYGIUM WILFORDII;

ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT COMPONENTS; PROSPECTIVE STUDIES; TRIPTERYGIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34347377577     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9747-y     Document Type: Article

References (27)

1. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ, European Crohn's and Colitis Organisation (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 (Suppl 1):i16-i35
2. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA (1979) National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 77:870-882
3. Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (Suppl 5):V1-V16
4. Tao XL, Lipsky PE (2000) The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 26:29-50
5. Lipsky PE, Tao XL (1997) A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 26:713-723
6. Tao XL, Davis L, Hashimoto K, Lipsky PE (1996) The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction. J Pharmacol Exp Ther 276:316-325
7. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, Kao PN (1999) Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 274:13443-13450
8. Huang FC, Chan WK, Moriarty KJ, Zhang DC, Chang MN, He W, Yu KT, Zilberstein A (1998) Novel cytokine release inhibitors. Part I: triterpenes. Bioorg Med Chem Lett 8:1883-1886
9. Li XW, Weir MR (1990) Radix Tripterygium wilfordii-a Chinese herbal medicine with potent immunosuppressive properties. Transplantation 50:82-86
10. Krakauer T, Chen X, Howard OM, Young HA (2005) Triptolide attenuates endotoxin- and staphylococcal exotoxin-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol 27:53-66
11. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent anti-oxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 25:1341-1357
12. Jin HZ, Hwang BY, Kim HS, Lee JH, Kim YH, Lee JJ (2002) Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF- kappaB activation and NO production. J Nat Prod 65:89-91
13. Chen L, Wang HJ, Zhao ZQ (2005) Effects of the extract of a Chinese herb Tripterygium wilfordii Hook F on rat pituitary gland. Am J Chin Med 33:945-955
14. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM (2004) TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappaB activation. Am J Physiol Gastrointest Liver Physiol 286:G367-G376
15. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter JI (1989) Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97:927-931
16. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD (2004) Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 322:778-786
17. Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170:2-6
18. Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439-444
19. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn's Disease Study Group (2001) An engineered human antibody to TNF (cdp571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330-1338
20. Mary JY, Modigliani R, for the Groupe d'Etudes Therapeutiques des Affections Inflammatoires duTube Digestif (GETAID) (1989) Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 30:983-989
21. Ho LJ, Lai JH (2004) Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr Drug Metab 5:181-192
22. Gu WZ, Banerjee S, Rauch J, Brandwein SR (1992) Suppression of renal disease and arthritis, and prolongation of survival in MRL-lpr mice treated with an extract of Tripterygium wilfordii Hook F. Arthritis Rheum 35:1381-1386
23. Kao NL, Richmond GW, Moy JN (1993) Resolution of severe lupus nephritis associated with Tripterygium wilfordii Hook F ingestion. Arthritis Rheum 36:1751-1752
24. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, Lochs H, Raedler A (1999) Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 353:459-461
25. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, Ding Y, Luo H, Hou W, Zhao Q, Liu N, Ren H, Hou X, Xu H (2006) Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 12:212-217
26. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E (1998) A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 339:370-374
27. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL (1993) Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 104:1293-1301